Top

Published in:

Open Access 22-09-2023 | Insulins | Review

Insulin Therapy for the Management of Diabetes Mellitus: A Narrative Review of Innovative Treatment Strategies

Authors: Ken M. Nkonge, Dennis K. Nkonge, Teresa N. Nkonge

Published in: Diabetes Therapy | Issue 11/2023

Abstract

The discovery of insulin was presented to the international medical community on May 3, 1922. Since then, insulin has become one of the most effective pharmacological agents used to treat type 1 and type 2 diabetes mellitus. However, the initiation and intensification of insulin therapy is often delayed in people living with type 2 diabetes due to numerous challenges associated with daily subcutaneous administration. Reducing the frequency of injections, using insulin pens instead of syringes and vials, simplifying treatment regimens, or administering insulin through alternative routes may help improve adherence to and persistence with insulin therapy among people living with diabetes. As the world commemorates the centennial of the commercialization of insulin, the aims of this article are to provide an overview of insulin therapy and to summarize clinically significant findings from phase 3 clinical trials evaluating less frequent dosing of insulin and the non-injectable administration of insulin.

Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE. The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev. 2020;41:733–55. PubMedPubMedCentralCrossRef

Wellington A. Leonard Thompson ‘ever remembered’: the first person to receive insulin. J Med Biogr. 2022;30:64–6. PubMedCrossRef

Best CH, Scott DA. The preparation of insulin. J Biol Chem. 1923;57:709–23. https://doi.org/10.1016/S0021-9258(18)85482-5. CrossRef

de Leiva-Hidalgo A, de Leiva-Pérez A. On the occasion of the centennial of insulin therapy (1922–2022), II-organotherapy of diabetes mellitus (1906–1923): acomatol. Pancreina. Insulin. Acta Diabetol. 2023;60:163–89. PubMedCrossRef

Abel JJ. Crystalline insulin. Proc Natl Acad Sci USA. 1926;12:132–6. https://doi.org/10.1073/pnas.12.2.132. CrossRefPubMedPubMedCentral

Crowfoot D. X-ray single crystal photographs of insulin. Nature. 1935;135:591–2. https://doi.org/10.1038/135591a0. CrossRef

Sanger F. Chemistry of insulin. Br Med Bull. 1960;16:183. https://doi.org/10.1093/oxfordjournals.bmb.a069832. CrossRefPubMed

Vecchio I, Tornali C, Bragazzi NL, Martini M. The discovery of insulin: an important milestone in the history of medicine. Front Endocrinol (Lausanne). 2018;9:613. PubMedCrossRef

Riggs AD. Making, cloning, and the expression of human insulin genes in bacteria: the path to humulin. Endocr Rev. 2021;42:374–80. PubMedCrossRef

10.

Garg SK, Rewers AH, Akturk HK. Ever-increasing insulin-requiring patients globally. Diabetes Technol Ther. 2018;20:S21-24. PubMedCrossRef

11.

Levitt M, Chothia C. Structural patterns in globular proteins. Nature. 1976;261:552–8. https://doi.org/10.1038/261552a0. CrossRefPubMed

12.

Rege NK, Liu M, Yang Y, et al. Evolution of insulin at the edge of foldability and its medical implications. Proc Natl Acad Sci USA. 2020;117:29618–28. PubMedPubMedCentralCrossRef

13.

Mayer JP, Zhang F, DiMarchi RD. Insulin structure and function. Biopolymers. 2007;88:687–713. PubMedCrossRef

14.

Bolli GB, Cheng AYY, Owens DR. Insulin: evolution of insulin formulations and their application in clinical practice over 100 years. Acta Diabetol. 2022;59:1129–44. PubMedPubMedCentralCrossRef

15.

Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab. 2017;19:3–12. PubMedCrossRef

16.

Gerritzen F. The duration of the action of different insulins. Br Med J. 1952;1:249–50. https://doi.org/10.1136/bmj.1.4752.249. CrossRefPubMedPubMedCentral

17.

Gerritzen F. The classification of various insulins. Br Med J. 1953;2:1030–1. https://doi.org/10.1136/bmj.2.4844.1030. CrossRefPubMedPubMedCentral

18.

Battelino T, Bosnyak Z, Danne T, et al. InRange: comparison of the second-generation basal insulin analogues glargine 300 U/mL and degludec 100 U/mL in persons with type 1 diabetes using continuous glucose monitoring–study design. Diabetes Ther. 2020;11:1017–27. PubMedPubMedCentralCrossRef

19.

Mauricio D, Hramiak I. Second-generation insulin analogues—a review of recent real-world data and forthcoming head-to-head comparisons. Eur Endocrinol. 2018;14:2–9. PubMedPubMedCentral

20.

Frohnert BI, Alonso GT. Challenges in delivering smaller doses of insulin. Diabetes Technol Ther. 2015;17:597–9. PubMedPubMedCentralCrossRef

21.

Sinding C. Making the unit of insulin: standards, clinical work, and industry, 1920–1925. Bull Hist Med. 2002;76:231–70. PubMedCrossRef

22.

Schloot NC, Hood RC, Corrigan SM, Panek RL, Heise T. Concentrated insulins in current clinical practice. Diabetes Res Clin Pract. 2019;148:93–101. PubMedCrossRef

23.

Madsbad S. LY2605541—a preferential hepato-specific insulin analogue. Diabetes. 2014;63:390–2. PubMedCrossRef

24.

Matli MC, Wilson AB, Rappsilber LM, Sheffield FP, Farlow ML, Johnson JL. The first interchangeable biosimilar insulin: insulin glargine-yfgn. J Diabetes Sci Technol. 2023;17:490–4. PubMedCrossRef

25.

Cunningham SM, Tanner DA. A review: the prospect of inhaled insulin therapy via vibrating mesh technology to treat diabetes. Int J Environ Res Public Health. 2020;17:5795. PubMedPubMedCentralCrossRef

26.

Zizzari AT, Pliatsika D, Gall FM, Fischer T, Riedl R. New perspectives in oral peptide delivery. Drug Discov Today. 2021;26:1097–105. PubMedCrossRef

27.

Wong EY, Kroon L. Ultra-rapid-acting insulins: how fast is really needed? Clin Diabetes. 2021;39:415–23. PubMedPubMedCentralCrossRef

28.

Rosenstock J, Del Prato S. Basal weekly insulins: the way of the future! Metabolism. 2022;126: 154924. PubMedCrossRef

29.

Mehta R, Chen R, Hirose T, et al. Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines. Diabetes Obes Metab. 2020;22:1961–75. PubMedPubMedCentralCrossRef

30.

Blumer I, Pettus JH, Cavaiola TS. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations. Postgrad Med. 2018;130:375–80. PubMedCrossRef

31.

Guerci B, Chanan N, Kaur S, Jasso-Mosqueda J, Lew E. Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Ther. 2019;10:437–49. PubMedPubMedCentralCrossRef

32.

Matteucci E, Giampietro O, Covolan V, Giustarini D, Fanti P, Rossi R. Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery. Drug Des Dev Ther. 2015;9:3109–18. CrossRef

33.

Munshi M, Neumiller JJ. Liberalisation, deintensification, and simplification in diabetes management: words matter. Lancet Diabetes Endocrinol. 2020;8:95–7. PubMedCrossRef

34.

Steenkamp D, Eby EL, Gulati N, Liao B. Adherence and persistence to insulin therapy in people with diabetes: impact of connected insulin pen delivery ecosystem. J Diabetes Sci Technol. 2022;16:995–1002. PubMedCrossRef

35.

Jude EB, Malecki MT, Huelgas RG, et al. Expert panel guidance and narrative review of treatment simplification of complex insulin regimens to improve outcomes in type 2 diabetes. Diabetes Ther. 2022;13:619–34. PubMedPubMedCentralCrossRef

36.

Masierek M, Nabrdalik K, Janota O, Kwiendacz H, Macherski M, Gumprecht J. The review of insulin pens–past, present, and look to the future. Front Endocrinol (Lausanne). 2022;13: 827484. PubMedCrossRef

37.

Mehta R, Goldenberg R, Katselnik D, Kuritzky L. Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. Ann Med. 2021;53:998–1009. PubMedPubMedCentralCrossRef

38.

Edgerton DS, Scott M, Farmer B, et al. Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery. JCI Insight. 2019;5: e126974. PubMedCrossRef

39.

Edgerton DS, Moore MC, Gregory JM, Kraft G, Cherrington AD. Importance of the route of insulin delivery to its control of glucose metabolism. Am J Physiol Endocrinol Metab. 2021;320:E891–7. PubMedPubMedCentralCrossRef

40.

Russell-Jones DL. Hepato-preferential insulins: Is this the end, or the end of the beginning? Diabetes Obes Metab. 2016;18:1053–4. PubMedPubMedCentralCrossRef

41.

Muñoz-Garach A, Molina-Vega M, Tinahones FJ. How can a good idea fail? Basal insulin peglispro [LY2605541] for the treatment of type 2 diabetes. Diabetes Ther. 2017;8:9–22. PubMedCrossRef

42.

Garg S, Dreyer M, Jinnouchi H, et al. A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1. Diabetes Obes Metab. 2016;18(Suppl 2):25–33. PubMedCrossRef

43.

Davies MJ, Russell-Jones D, Selam JL, et al. Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial. Diabetes Obes Metab. 2016;18:1055–64. PubMedPubMedCentralCrossRef

44.

Bergenstal RM, Lunt H, Franek E, et al. Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes Metab. 2016;18:1081–8. PubMedPubMedCentralCrossRef

45.

Blevins T, Pieber TR, Colón Vega G, et al. Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. Diabetes Obes Metab. 2016;18:1072–80. PubMedPubMedCentralCrossRef

46.

Buse JB, Rodbard HW, Trescoli Serrano C, et al. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes previously treated with basal insulin: IMAGINE 5. Diabetes Care. 2016;39:92–100. PubMedCrossRef

47.

Grunberger G, Chen L, Rodriguez A, et al. A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial. Diabetes Obes Metab. 2016;18(Suppl 2):34–42. PubMedCrossRef

48.

Garg S, Selam JL, Bhargava A, et al. Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study. Diabetes Obes Metab. 2016;18(Suppl 2):43–9. PubMedCrossRef

49.

Harris C, Forst T, Heise T, et al. Hypoglycemia risk related to double dose is markedly reduced with type 2 diabetes mellitus in a randomized trial: IMAGINE 8. Diabetes Technol Ther. 2017;19:463–70. PubMedPubMedCentralCrossRef

50.

Hirose T. Development of new basal insulin peglispro (LY2605541) ends in a disappointing result. Diabetol Int. 2016;7:16–7. PubMedPubMedCentralCrossRef

51.

Rosenstock J, Bain SC, Gowda A, et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Eng J Med. 2023;389:297–308. CrossRef

52.

Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open-label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11:414–25. PubMedCrossRef

53.

Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naïve type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA. 2023;330:228–37. PubMedCrossRef

54.

Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401:1929–40. PubMedCrossRef

55.

ClinicalTrials.gov. A research study to compare a new weekly insulin, insulin icodec used with doseguide app, and daily insulins in people with type 2 diabetes who have not used insulin before (ONWARDS 5). 2021. https://clinicaltrials.gov/study/NCT04760626. Accessed 10 Mar 2023.

56.

ClinicalTrials.gov. A research study to compare a new weekly insulin, insulin icodec, and an available daily insulin, insulin degludec, both in combination with mealtime insulin in people with type 1 diabetes (ONWARDS 6) (ONWARDS 6). 2021. https://clinicaltrials.gov/study/NCT04848480. Accessed 10 Mar 2023.

57.

ClinicalTrials.gov. A research study to see how well the new weekly medicine icosema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to weekly insulin icodec (COMBINE 1). 2022. https://clinicaltrials.gov/study/NCT05352815. Accessed 10 Mar 2023.

58.

ClinicalTrials.gov. A research study to see how well the new weekly medicine icosema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to weekly semaglutide (COMBINE 2) (COMBINE 2). 2022. https://clinicaltrials.gov/study/NCT05259033. Accessed 10 Mar 2023.

59.

ClinicalTrials.gov. A research study to see how well the new weekly medicine icosema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to insulin glargine taken daily with insulin aspart (COMBINE 3). 2022. https://clinicaltrials.gov/study/NCT05013229. Accessed 10 Mar 2023.

60.

ClinicalTrials.gov. A study of insulin efsitora alfa (LY3209590) compared to glargine in adult participants with type 2 diabetes who are starting basal insulin for the first time (QWINT-1) (QWINT-1). 2022. https://clinicaltrials.gov/study/NCT05662332. Accessed 2 Apr 2023.

61.

ClinicalTrials.gov. A study of insulin efsitora alfa (LY3209590) compared to degludec in adults with type 2 diabetes who are starting basal insulin for the first time (QWINT-2). 2022. https://clinicaltrials.gov/study/NCT05362058. Accessed 2 Apr 2023.

62.

ClinicalTrials.gov. A study of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 2 diabetes currently treated with basal insulin. 2022. https://clinicaltrials.gov/study/NCT05275400. Accessed 2 Apr 2023.

63.

ClinicalTrials.gov. A study of insulin efsitora alfa (LY3209590) as a weekly basal insulin compared to insulin glargine in adult participants with type 2 diabetes on multiple daily injections (QWINT-4). 2022. https://clinicaltrials.gov/study/NCT05462756. Accessed 2 Apr 2023.

64.

ClinicalTrials.gov. A study of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy (QWINT-5). 2022. https://clinicaltrials.gov/study/NCT05463744. Accessed 2 Apr 2023.

65.

Barnett A, Begg A, Dyson P, Feher M, Hamilton S, Munro N. Insulin for type 2 diabetes: choosing a second-line insulin regimen. Int J Clin Pract. 2008;62:1647–53. PubMedCrossRef

66.

Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2016;32:21–39. PubMedCrossRef

67.

Pfützner A, Sachsenheimer D, Grenningloh M, et al. Using insulin infusion sets in CSII for longer than the recommended usage time leads to a high risk for adverse events: results from a prospective randomized crossover study. J Diabetes Sci Technol. 2015;9:1292–8. PubMedPubMedCentralCrossRef

68.

Thethi TK, Rao A, Kawji H, et al. Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications. 2010;24:73–8. PubMedCrossRef

69.

Lee DS, Lee H. Adherence and persistence rates of major antidiabetic medications: a review. Diabetol Metab Syndr. 2022;14:12. PubMedPubMedCentralCrossRef

70.

Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20:488–96. PubMedCrossRef

71.

Edelman S, Cassarino D, Kayne D, Dex T, Li X, Pasquel FJ. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist. J Manag Care Spec Pharm. 2022;28:958–68. PubMed

72.

Spain CV, Wright JJ, Hahn RM, Wivel A, Martin AA. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin Ther. 2016;38:1653–64. PubMedCrossRef

73.

Polonsky WH, Arora R, Faurby M, Fernandes J, Liebl A. Higher rates of persistence and adherence in patients with type 2 diabetes initiating once-weekly vs daily injectable glucagon-like peptide-1 receptor agonists in US clinical practice (STAY Study). Diabetes Ther. 2022;13:175–87. PubMedCrossRef

74.

Bajaj HS, Goldenberg RM. Insulin icodec weekly: a basal insulin analogue for type 2 diabetes. touchREV Endocrinol. 2023;19:4–6. PubMedPubMedCentralCrossRef

75.

Capoccia K, Odegard PS, Letassy N. Medication adherence with diabetes medication: a systematic review of the literature. Diabetes Educ. 2016;42:34–71. PubMedCrossRef

76.

Alsaidan AA, Alsaidan OA, Mallhi TH, Khan YH, Alzarea AI, Alanazi AS. Assessment of adherence to insulin injections among diabetic patients on basal-bolus regimen in primary and secondary healthcare centers in Al-Jouf region of Saudi Arabia; a descriptive analysis. J Clin Med. 2023;12:3474. PubMedPubMedCentralCrossRef

77.

Bellary S, Barnett AH. Insulin icodec: evolution or revolution in diabetes therapy? Lancet Diabetes Endocrinol. 2023;11:379–80. PubMedCrossRef

78.

Manuel CR, Haeusler RA. Insulin-stimulated lipogenesis gets an epigenetic makeover. J Clin Invest. 2020;130:2809–10. PubMedPubMedCentralCrossRef

79.

Santoleri D, Titchenell PM. Resolving the paradox of hepatic insulin resistance. Cell Mol Gastroenterol Hepatol. 2019;7:447–56. PubMedCrossRef

80.

Kurtzhals P, Nishimura E, Haahr H, et al. Commemorating insulin’s centennial: engineering insulin pharmacology towards physiology. Trends Pharmacol Sci. 2021;42:620–39. PubMedCrossRef

81.

Batchuluun B, Pinkosky SL, Steinberg GR. Lipogenesis inhibitors: therapeutic opportunities and challenges. Nat Rev Drug Discov. 2022;21:283–305. PubMedPubMedCentralCrossRef

82.

Hvid H, Brand CL, Hummelshøj T, et al. Preclinical exploration of combined glucagon inhibition and liver-preferential insulin for treatment of diabetes using in vitro assays and rat and mouse models. Diabetologia. 2023;66:376–89. PubMedCrossRef

83.

Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care. 2019;42:1593–603. PubMedPubMedCentralCrossRef

84.

Dovc K, Battelino T. Time in range centered diabetes care. Clin Pediatr Endocrinol. 2021;30:1–10. PubMedPubMedCentralCrossRef

85.

Saboo B, Kesavadev J, Shankar A, et al. Time-in-range as a target in type 2 diabetes: an urgent need. Heliyon. 2021;7: e05967. PubMedPubMedCentralCrossRef

86.

Aleppo G. Clinical application of time in range and other metrics. Diabetes Spectr. 2021;34:109–18. PubMedPubMedCentralCrossRef

87.

Moyers JS, Hansen RJ, Day JW, et al. Preclinical characterization of LY3209590, a novel weekly basal insulin Fc-fusion protein. JPET. 2022;382:346–55. https://doi.org/10.1124/jpet.122.001105. CrossRef

88.

Lisco G, De Tullio A, Disoteo O, et al. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: a rapid review of randomized controlled trials and meta-analysis. Front Endocrinol (Lausanne). 2022;13: 920541. PubMedCrossRef

89.

Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 2023;14:1161521. PubMedCrossRef

90.

Robinson S, Newson RS, Liao B, Kennedy-Martin T, Battelino T. Missed and mistimed insulin doses in people with diabetes: a systematic literature review. Diabetes Technol Ther. 2021;23:844–56. PubMedCrossRef

91.

Pandey M, Choudhury H, Yi CX, et al. Recent updates on novel approaches in insulin drug delivery: a review of challenges and pharmaceutical implications. Curr Drug Targets. 2018;19:1782–800. PubMedCrossRef

92.

Rosenstock J, Cefalu WT, Hollander PA, et al. Two-year pulmonary safety and efficacy of inhaled human insulin (exubera) in adult patients with type 2 diabetes. Diabetes Care. 2008;31:1723–8. PubMedPubMedCentralCrossRef

93.

Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W, Inhaled Human Insulin Type 1 Diabetes Study Group. Two-year safety and efficacy of inhaled human insulin (exubera) in adult patients with type 1 diabetes. Diabetes Care. 2007;30:579–85. PubMedCrossRef

94.

Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care. 2006;29:1282–7. PubMedCrossRef

95.

Quattrin T, Bélanger A, Bohannon NJV, Schwartz SL, Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27:2622–7. PubMedCrossRef

96.

Skyler JS, Weinstock RS, Raskin P, et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care. 2005;28:1630–5. PubMedCrossRef

97.

Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2005;143:549–58. PubMedCrossRef

98.

Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27:2356–62. PubMedCrossRef

99.

Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled technosphere insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab. 2012;14:163–73. PubMedCrossRef

100.

Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375:2244–53. PubMedCrossRef

101.

Bode BW, McGill JB, Lorber DL, et al. Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015;38:2266–73. PubMedCrossRef

102.

Rosenstock J, Franco D, Korpachev V, et al. Inhaled technosphere insulin versus inhaled technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. Diabetes Care. 2015;38:2274–81. PubMedCrossRef

103.

Hoogwerf BJ, Pantalone KM, Basina M, Jones MC, Grant M, Kendall DM. Results of a 24-week trial of technosphere insulin versus insulin aspart in type 2 diabetes. Endocr Pract. 2021;27:38–43. PubMedCrossRef

104.

McGill JB, Weiss D, Grant M, Jones MC, Kendall DM, Hoogwerf BJ. Understanding inhaled technosphere insulin: results of an early randomized trial in type 1 diabetes mellitus. J Diabetes. 2021;13:164–72. PubMedCrossRef

105.

ClinicalTrials.gov. Afrezza ^® INHALE-1 Study in Pediatrics (INHALE-1). 2021. https://clinicaltrials.gov/study/NCT04974528. Accessed 26 Apr 2023.

106.

ClinicalTrials.gov. Study to evaluate the efficacy and safety of ORMD-0801 in subjects with type 2 diabetes mellitus. 2020. https://clinicaltrials.gov/study/NCT04606576. Accessed 26 Apr 2023.

107.

ClinicalTrials.gov. A phase 3 study to evaluate the efficacy and safety of ORMD-0801 in subjects with type 2 diabetes mellitus. 2021. https://clinicaltrials.gov/study/NCT04754334. Accessed 26 Apr 2023.

108.

Harrison GA. Insulin in alcoholic solution by the mouth. Br Med J. 1923;2:1204–5. https://doi.org/10.1136/bmj.2.3286.1204. CrossRefPubMedPubMedCentral

109.

Gänsslen M. Über inhalation von insulin. Klin Wochenschr. 1925;4:71. https://doi.org/10.1007/BF01748135. CrossRef

110.

Chakravarty A, Panchagnula MV, Mohan A, Patankar NA. Pulmonary drug delivery and retention: a computational study to identify plausible parameters based on a coupled airway-mucus flow model. PLoS Comput Biol. 2022;18: e1010143. PubMedPubMedCentralCrossRef

111.

Angelo R, Rousseau K, Grant M, Leone-Bay A, Richardson P. Technosphere insulin: defining the role of technosphere particles at the cellular level. J Diabetes Sci Technol. 2009;3:545–54. PubMedPubMedCentralCrossRef

112.

White S, Bennett DB, Cheu S, et al. EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther. 2005;7:896–906. PubMedCrossRef

113.

Heinemann L. The failure of exubera: are we beating a dead horse? J Diabetes Sci Technol. 2008;2:518–29. PubMedPubMedCentralCrossRef

114.

Mathieu C, Gale EAM. Inhaled insulin: gone with the wind? Diabetologia. 2008;51:1–5. PubMedCrossRef

115.

Klonoff DC. Afrezza inhaled insulin: the fastest-acting FDA-approved insulin on the market has favorable properties. J Diabetes Sci Technol. 2014;8:1071–3. PubMedPubMedCentralCrossRef

116.

Bellary S, Barnett AH. Review: inhaled insulin: overcoming barriers to insulin therapy? Br J Diabetes Vasc Dis. 2006;6:103–8. CrossRef

117.

Guntur VP, Dhand R. Inhaled insulin: extending the horizons of inhalation therapy. Respir Care. 2007;52:911–22. PubMed

118.

Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care. 2001;24:1556–9. PubMedCrossRef

119.

Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet. 2001;357:331–5. PubMedCrossRef

120.

Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther. 2002;24:552–64. PubMedCrossRef

121.

Hayes RP, Muchmore D, Schmitke J. Efffect of inhaled insulin on patient-reported outcomes and treatment preference in patients with type 1 diabetes. Curr Med Res Opin. 2007;23:435–42. PubMedCrossRef

122.

Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (exubera) in patients with type 1 or type 2 diabetes. Diabetes Care. 2004;27:1318–23. PubMedCrossRef

123.

Testa MA, Simonson DC. Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes. Diabetes Care. 2007;30:1399–405. PubMedCrossRef

124.

Khunti K, Almalki M, Chan JCN, Amod A. The role of real-world evidence in treatment decision-making, regulatory assessment, and understanding the perspectives of people with type 2 diabetes: examples with gliclazide MR. Diabetes Ther. 2023. https://doi.org/10.1007/s13300-023-01458-6. CrossRefPubMedPubMedCentral

125.

Gedawy A, Martinez J, Al-Salami H, Dass CR. Oral insulin delivery: existing barriers and current counter-strategies. J Pharm Pharmacol. 2018;70:197–213. PubMedCrossRef

Title: Insulin Therapy for the Management of Diabetes Mellitus: A Narrative Review of Innovative Treatment Strategies
Authors: Ken M. Nkonge
Dennis K. Nkonge
Teresa N. Nkonge
Publication date: 22-09-2023
Publisher: Springer Healthcare
Keywords: Insulins
Insulins
Oral Antidiabetic Drugs
Diabetes
Type 2 Diabetes
Semaglutide
Type 1 Diabetes
Published in: Diabetes Therapy / Issue 11/2023
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI: https://doi.org/10.1007/s13300-023-01468-4

Webinar | 08-11-2023 | 18:00 (CET)

Keynote Webinar | Spotlight on Diet and Diabetes

Watch now

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.

Prof. Mike Lean

Prof. Falko Sniehotta

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2023

Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study

Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia

Optimising Insulin Injection Techniques to Improve Diabetes Outcomes

Correction to: Prevalence of Diabetic Kidney Disease with Different Subtypes in Hospitalized Patients with Diabetes and Correlation Between eGFR and LncRNA XIST Expression in PBMCs

Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations

Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes

Keynote Webinar | Spotlight on Diet and Diabetes